Essential thrombocythemia treatment algorithm 2018

Current drug therapy for myeloproliferative neoplasms, including essential thrombocythemia (ET) and polycythemia vera (PV), is neither curative nor has it been shown to prolong survival. Fortunately, prognosis in ET and PV is relatively good, with median survivals in younger patients estimated at 33...

Descripción completa

Detalles Bibliográficos
Autores principales: Tefferi, Ayalew, Vannucchi, Alessandro M., Barbui, Tiziano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Current Treatment Algorithm
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802626/
https://www.ncbi.nlm.nih.gov/pubmed/29321520
http://dx.doi.org/10.1038/s41408-017-0041-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802626/
https://www.ncbi.nlm.nih.gov/pubmed/29321520
http://dx.doi.org/10.1038/s41408-017-0041-8

Ejemplares similares